Derek Lowe's commentary on drug discovery and the pharma industry. An editorially independent blog from the publishers of Science Translational Medicine. All content is Derek’s own, and he does not in any way speak for his employer.

By Derek Lowe

Posts tagged with "Press Coverage"

• Alzheimer's Disease

  Neurotrope: A Shameful PR Stunt

  3 May, 2017

  There was some Alzheimer’s news the other day, but it wasn’t actually about Alzheimer’s. Not very much. It was more about hype, press releases, and a grievous lack of understanding of statistics. Via @AndyBiotech and @biotechtoreador on Twitter, I came across this release about an announcement from a small company called Neurot… Read More

• Drug Prices

  Those Australian Students And Their Daraprim

  1 December, 2016

  OK, enough people have emailed me the press coverage of the students in Sydney making daraprim, which is the drug that Martin Shkreli’s former firm has famously jacked up the price of. From what I can see, a lot of the news stories on this are missing the point. Daraprim is not hard to make in… Read More

• Alzheimer's Disease

  The Limits of Big Data

  21 October, 2016

  I fear that mentioning the phrase “Big Data” in the first sentence of a blog post will make half the potential readers suddenly remember that they have podiatrist appointments or something. But that’s the only way to approach this article at Wired. After all, the title is “The Cure For Cancer is Data – Mountains of… Read More

• Cancer

  Better, Faster, More Comprehensive Manure Distribution

  21 September, 2016

  So today brings news that Microsoft is working on curing cancer in the next five or ten years. That, I’m sure, will come as a relief, especially to those people who’ve had the company’s software crash on them recently. For some reason, the UK press is especially susceptible to Amazing Cancer Cure stories (and to… Read More

• Cancer

  Precision Oncology Isn’t Quite There Yet

  12 September, 2016

  Here’s a gauntlet thrown down – let’s see how many people show up to the duel. Vinay Prasad has a piece in Nature titled “The Precision Oncology Illusion”, with the subhead saying “Precision oncology has not been shown to work, and perhaps it never will”. (Here’s Prasad earlier this year, with co-auth… Read More

• Analytical Chemistry

  Not So Verily

  7 June, 2016

  The folks at Stat clearly have some good sources inside Google’s Verily startup. They ran a story back in March about problems with the CEO (blogged about here), and now they’re back with more opinion from within. This piece has a number of people expressing dissatisfaction with how Verily’s three big projects are actually going… Read More

• Business and Markets

  Getting the Indian Drug Scandals Straight

  7 January, 2016

  An old colleague of mine sent along this story from India. It’s about the problems that GVK Bio had in 2015, which led to all sorts of consequences: In October this year, a national newspaper in India ran a front page news item with the headline “A love story that cost GVK its international reputation”. The story… Read More

• Cancer

  Antibiotics: Not As Easy As They Say

  18 November, 2015

  Since we were just talking yesterday about antibiotics and the misconceptions that people have about them, this is an appropriate time to take a look at an article in the popular press about antibiotic discovery. (Vice.com counts as “popular press”, for sure). The article focuses on the work of Brian Murphy at UI-Chicago, who’s do… Read More

• Drug Development

  Idiocy On Drug Research Costs

  9 November, 2015

  Here’s a piece from the Center for Economic and Policy Research that claims to have the whole high-drug-price problem figured out. It’s “incredibly inefficient research”, just so you know. How does the CEPR know, you ask? They do a comparison of the costs of research (as provided by the Center for the Study of Drug Developm… Read More

• Press Coverage

  Statnews Launches

  5 November, 2015

  I wanted to mention a new pharma/health news source, Statnews. This is a venture of the Boston Globe, recognizing that the Boston/Cambridge area has a massive presence in this field and that a dedicated news organization could do a lot here. They’ve assembled an excellent team of journalists, and anyone who’s followed science reporting… Read More